West Pharmaceutical Services said consolidated net sales for the 3 months ended March 31, 2025 increased by $2.6 million, or 0.4%, including an unfavorable foreign currency translation impact of $11.7 million. Excluding foreign currency translation effects, consolidated net sales increased by $14.3 million, or 2.1%.

1. 01

   West Pharmaceutical Services said consolidated net sales for the 3 months ended March 31, 2025 increased by $2.6 million, or 0.4%, including an unfavorable foreign currency translation impact of $11.7 million. Excluding foreign currency translation effects, consolidated net sales increased by $14.3 million, or 2.1%.

2. 02

   West Pharmaceutical said consolidated gross profit for the 3 months ended March increased by $1.7 million, or 0.7%, with Proprietary Products gross profit margin rising by 0.3 margin points and Contract-Manufactured Products gross profit margin declining by 0.9 margin points. The company cited plant spend for additional manufacturing capacity to support the GLP-1 business as a factor in the latter.

3. 03

   West Pharmaceutical Services said consolidated operating profit for the 3 months decreased by $15.8 million, or 12.9%. During the same period, the company recorded restructuring and related charges of $17.8 million, of which $16.4 million was reflected in other expense (income) in connection with the 2025 restructuring plan.

4. 04

   The company said it repurchased 550,281 shares during Q1 2025 at an average price of $242.63 per share for a total cost of $133.5 million. As of March 31, 2025, the company had no outstanding borrowings under its multi-currency revolving credit facility, with available borrowing capacity of $497.7 million.

Key figures

Quarter ended March 31, 2025

Revenue

$698M

Operating income

$107M

Net income

$90M

EPS

$1.23

Gross profit

$232M

Operating cash flow

$129M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.